Kura Oncology ( (KURA) ) has provided an update.
Kura Oncology, Inc. has appointed Michael J. Vasconcelles, M.D. as a new Class III director with a term lasting until the 2026 annual stockholders’ meeting, and as a member of the Compensation Committee. Dr. Vasconcelles’ selection was independent of any outside arrangements, and he will be compensated with an annual cash retainer and stock options as per the company’s Compensation Policy. His compensation includes a $40,000 annual retainer, additional committee service fees, and significant stock options that vest over time, with full vesting upon a change in control.
For an in-depth examination of KURA stock, go to TipRanks’ Stock Analysis page.
